Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05799053
Other study ID # NL78304.100.21
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 12, 2022
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source St. Antonius Hospital
Contact Koen Vermeijden, MD
Phone (+31) 020-566 2906
Email k.vermeijden@antoniusziekenhuis.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Peppermint oil has shown to be effective in the treatment of Irritable Bowel Syndrome (IBS) symptoms in adults. Few studies of low quality are performed in an paediatric setting. Therefore, the investigators will conduct a multicenter randomized, placebo controlled trial to investigate the effects of an eight-week peppermint oil treatment in paediatric IBS or Functional Abdominal Pain - Not otherwise specified (FAP-NOS) patients.


Description:

The objective of the MINT study is to investigate the effectiveness of peppermint oil capsules compared to placebo capsules in reducing abdominal pain intensity in children with IBS or FAP-NOS. In addition, we evaluate the effect of peppermint oil capsules compared to placebo capsules on other disease-related outcome measures such as anxiety & depression, quality of life, absenteeism from school, and healthcare costs. The second aim is to explore the effectiveness of regular mints in reducing abdominal pain intensity compared to peppermint oil capsules and placebo capsules and the effect of mints on secondary outcome parameters.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date December 31, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 8 Years to 17 Years
Eligibility Inclusion Criteria: - Children aged between 8 years and 18 years - Diagnosis of IBS or FAP-NOS according to the Rome IV criteria. According to these criteria, organic disorders will be ruled out after routine laboratory testing initiated by their general practitioner or treating physician as part of standard of care. In patients without alarm symptoms only celiac screening (anti-transglutaminase antibodies and IgA), and faecal calprotectin are necessary.37 In patients with diarrhea faecal testing for Giardia Lambliae will be added. If alarm symptoms are present, further diagnostic testing (like a full blood count, CRP, liver tests or an ultrasound) to rule out an organic disorder, is left to the discretion of the treating physician. - An average daily pain rate of = 3 of 10 on the Wong Baker Faces Pain Scale (This is a validated pain scale to measure pain intensity). Informed Consent by both parents and by children aged = 12 years. No informed consent from parents is necessary for children >16 years. Exclusion Criteria: - Current treatment by another health care professional for abdominal symptoms - Previous use of peppermint oil for these abdominal complaints - Known hypersensitivity to mints or peppermint oil - Gastrointestinal blood loss - Recurrent or unexplained fevers - Decreased growth velocity - History of previous abdominal surgeries in the past 3 months - Significant chronic health condition requiring specialty care (e.g., lithiasis, ureteropelvic junction obstruction, sickle cell, cerebral palsy, hepatic, hematopoietic, renal, endocrine, or metabolic diseases) that could potentially impact the child's ability to participate or confound the results of the study - Known concomitant organic gastrointestinal disease - Current use of drugs which influence gastrointestinal motility, such as erythromycin, azithromycin, butyl scopolamine, domperidone, mebeverine and Iberogast. If laxatives are being used (in patients with IBS-C) they can continue using them during the study. - Current use of proton-pump inhibitors - Insufficient knowledge of the Dutch language - Pregnancy or current lactation. Women with childbearing potential must have a negative urine pregnancy test within 7 days prior to first dose of study treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Small intestinal release peppermint oil
Tempocol®, a gastric acid resistant (enteric-coated) capsule containing 182mg of Menthae Piperitae Aetheroleum (peppermint oil), is currently registered as an over the counter prescription drug on the Dutch market for treatment of abdominal pain, discomfort or flatulence.
Peppermint sweets
Wilhelmina® peppermints contain 9.2 mg of Menthae Piperitae Aetheroleum (peppermint oil), and 18.4 Kcal per mint and are to be taken orally.
Placebo
Capsule containing microcrystalline cellulose

Locations

Country Name City State
Netherlands De KinderKliniek Almere Flevoland
Netherlands Amsterdam UMC Amsterdam Noord-Holland
Netherlands Amphia Hospital Breda Noord-Brabant

Sponsors (1)

Lead Sponsor Collaborator
St. Antonius Hospital

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Abdominal pain intensity response rate after 8 weeks of treatment The proportion of patients with = 30% reduction of their abdominal pain intensity after 8 weeks of therapy compared to baseline. This will be assessed by a smartphone diary app, on which patients record daily at the end of the day the intensity of their abdominal pain during a period of 7 consecutive days using a 10 point Likert scale/Wong-Baker faces scale. A score of 0 correlates with no pain and a score of 10 correlates with the worst imaginable pain. The intensity scores of 7 days will be summed up. 8 weeks
Secondary Change in pain duration Abdominal pain duration will be scored in minutes of abdominal pain per day during 7 consecutive days after 8 weeks of therapy compared to baseline 4 weeks, 8 weeks, 12 weeks
Secondary Change in pain frequency Abdominal pain frequency will be scored as the average amount of days with pain during 7 consecutive days after 8 weeks of therapy compared to baseline 4 weeks, 8 weeks, 12 weeks
Secondary Change in abdominal pain intensity Abdominal pain intensity will be scored using a 10-point Wong-Baker faces scale during 7 consecutive days after 8 weeks of therapy compared to baseline 4 weeks, 8 weeks, 12 weeks
Secondary Change in Quality of Life Change in quality of live will be measured with the PedsQL after 8 weeks of therapy compared to baseline 8 weeks
Secondary Change in depression and anxiety score Depression and anxiety scores are measured by the Revised Anxiety and Depression Scale-short version (RCADS-25) after 8 weeks of therapy compared to baseline 8 weeks
Secondary School absences during the treatment Hours of school absence in the previous week are measured. 4 weeks, 8 weeks, 12 weeks
Secondary Use of pain rescue medication during the treatment Use of pain rescue medication like paracetamol or NSAIDs 4 weeks, 8 weeks, 12 weeks
Secondary Expectancy of treatment expectations of both parents separately of the treatment on a scale of 0 (no improvement) to 10 (very much improved) 0 weeks
Secondary Expectancy of treatment the child's expectations of the treatment on a scale of 0 (no improvement) to 10 (very much improved) 0 weeks
Secondary Change in defecation pattern Change in defecation pattern is recorded as the daily stool frequency and consistency according to the Bristol Stool Scale 4 weeks, 8 weeks, 12 weeks
Secondary Adequate relief patients will be asked whether they have adequate relief of IBS/FAP-NOS symptoms using a single question ("Did you have adequate relief of IBS/FAP-NOS symptoms (abdominal discomfort/pain, bowel habits, and other symptoms like nausea and bloating) over the past week?") scored on a dichotomous scale (Yes/No) 4 weeks, 8 weeks, 12 weeks
Secondary Health status the EQ-5D-Y is a standardised questionnaire on health-related quality of life and will be used in the cost-effectiveness and cost-utility analysis 8 weeks
Secondary Costs iMCQ and the iPCQ will be used to measure the direct and indirect costs due to health care utilization and work absenteeism by parents 8 weeks, 12 weeks
Secondary Safety of peppermint oil incidence of adverse events will be reported by the participants 4 weeks, 8 weeks, 12 weeks
Secondary Ease of use of peppermint oil capsules, placebo capsules or peppermint sweets Ease of use of capsules or sweets will be scored after 8 weeks using a 5-point Likert scale with the following statement: the pills were easy to use and swallow: strongly disagree/disagree/neither agree nor disagree/agree/strongly agree. 8 weeks
Secondary Taste of peppermint oil capsules, placebo capsules or peppermint sweets taste of capsules or sweets will be scored after 8 weeks using a Likert scale: I like the taste of the pills: strongly disagree/disagree/neither agree nor disagree/agree/strongly agree. 8 weeks
Secondary Placebo genes Several other single nucleotide polymorphisms (SNPs) were found to influence response to placebo treatment. Therefore, we will investigate whether SNPs in a candidate set of genes (previously associated with either the placebo response in adults) are related to either placebo response or treatment response in children with IBS or FAP-NOS. 0 weeks
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A